journal article·2018-11-05Open access

Development of transethosomes formulation for dermal fisetin delivery: Box–Behnken design, optimization, in vitro skin penetration, vesicles–skin interaction and dermatokinetic studies

Thasleem Moolakkadath, Mohd. Aqil, Abdul Ahad, Syed Sarim Imam, Babar Iqbal, Yasmin Sultana, Mohd Mujeeb, Zeenat Iqbal

Abstract

/h. The TEM image of optimized formulation exhibited sealed and spherical shape vesicles. Results of thermoanalytical techniques demonstrated that the prepared transethosomes vesicles formulation had fluidized the rigid membrane of rat's skin for smoother penetration of fisetin transethosomes. The confocal study results presented well distribution and penetration of Rhodamine B loaded transethosomes vesicles formulation up to deeper layers of the rat's skin as compared to the Rhodamine B-hydro alcoholic solution. Present study data revealed that the developed transethosomes vesicles formulation was found to be a potentially useful drug carrier for fisetin dermal delivery.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Bee Products Chemical Analysis · Skin Protection and Aging

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard (Deemed University)

Department of Pharmaceutics, College of Pharmacy, King Saud University

School of Pharmacy, Glocal University

Department of Pharmacognosy & Phytochemistry, School of Pharmaceutical Education and Research, Jamia Hamdard (Deemed University)

References (50)

Show source-provided references
1. 10.1016/j.abb.2010.12.00710.1016/j.abb.2010.12.007 ↗
2. Cohen JL. Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol. 2010;3:39–44.
3. 10.1038/nrc125310.1038/nrc1253 ↗
4. 10.1016/j.taap.2012.11.00210.1016/j.taap.2012.11.002 ↗
5. 10.1172/JCI3248110.1172/JCI32481 ↗
6. 10.1016/j.canlet.2008.02.05010.1016/j.canlet.2008.02.050 ↗
7. 10.1093/jn/130.9.224310.1093/jn/130.9.2243 ↗
8. 10.1038/jid.2011.610.1038/jid.2011.6 ↗
9. 10.1002/ijc.2617810.1002/ijc.26178 ↗
10. Hou DX, Fukuda M, Johnson JA, et al. Fisetin induces transcription of NADPH:quinone oxidoreductase gene through an antioxidant responsive element-involved activation. Int J Oncol. 2001;18:1175–1179.
11. 10.1111/php.1233710.1111/php.12337 ↗
12. 10.1111/exd.1218110.1111/exd.12181 ↗
13. 10.1371/journal.pone.008633810.1371/journal.pone.0086338 ↗
14. 10.1016/j.carbpol.2012.07.06010.1016/j.carbpol.2012.07.060 ↗
15. 10.1016/0024-3205(80)90268-410.1016/0024-3205(80)90268-4 ↗
16. 10.1016/S0378-5173(03)00183-210.1016/S0378-5173(03)00183-2 ↗
17. 10.1016/j.ijpharm.2008.04.03310.1016/j.ijpharm.2008.04.033 ↗
18. 10.1016/0005-2736(92)90154-E10.1016/0005-2736(92)90154-E ↗
19. 10.1080/21691401.2018.143070010.1080/21691401.2018.1430700 ↗
20. 10.1016/j.jsps.2017.01.00610.1016/j.jsps.2017.01.006 ↗
21. 10.1080/10837450.2017.133034510.1080/10837450.2017.1330345 ↗
22. 10.1016/j.nano.2011.06.00410.1016/j.nano.2011.06.004 ↗
23. 10.1615/CritRevTherDrugCarrierSyst.v13.i3-4.3010.1615/CritRevTherDrugCarrierSyst.v13.i3-4.30 ↗
24. 10.1016/j.ijpharm.2004.02.02410.1016/j.ijpharm.2004.02.024 ↗
25. 10.1016/S0168-3659(99)00222-910.1016/S0168-3659(99)00222-9 ↗
26. 10.2174/156720105436793110.2174/1567201054367931 ↗
27. 10.1016/j.ijbiomac.2014.03.01110.1016/j.ijbiomac.2014.03.011 ↗
28. 10.1016/j.ijpharm.2013.01.01110.1016/j.ijpharm.2013.01.011 ↗
29. 10.3109/21691401.2015.100850910.3109/21691401.2015.1008509 ↗
30. 10.1016/j.colsurfb.2011.12.00410.1016/j.colsurfb.2011.12.004 ↗
31. 10.2147/IJN.S10501610.2147/IJN.S105016 ↗
32. 10.1208/s12249-018-0951-110.1208/s12249-018-0951-1 ↗
33. 10.1016/j.ijbiomac.2017.05.12910.1016/j.ijbiomac.2017.05.129 ↗
34. 10.1016/j.msec.2017.02.14910.1016/j.msec.2017.02.149 ↗
35. 10.3109/13880209.2015.110063910.3109/13880209.2015.1100639 ↗
36. 10.2174/15672011179447990710.2174/156720111794479907 ↗
37. 10.1517/17425247.2014.91402710.1517/17425247.2014.914027 ↗
38. 10.3109/03639045.2010.53221910.3109/03639045.2010.532219 ↗
39. 10.1021/am506689310.1021/am5066893 ↗
40. 10.1016/j.ijpharm.2016.03.03010.1016/j.ijpharm.2016.03.030 ↗
41. 10.1016/j.biopha.2017.01.16410.1016/j.biopha.2017.01.164 ↗
42. 10.1016/j.ijbiomac.2013.11.01810.1016/j.ijbiomac.2013.11.018 ↗
43. 10.1016/j.molliq.2018.01.14110.1016/j.molliq.2018.01.141 ↗
44. 10.3109/02652048.2015.104651310.3109/02652048.2015.1046513 ↗
45. 10.1016/j.jconrel.2007.08.00510.1016/j.jconrel.2007.08.005 ↗
46. 10.1016/j.ijpharm.2010.06.03410.1016/j.ijpharm.2010.06.034 ↗
47. 10.1016/S0168-3659(98)00152-710.1016/S0168-3659(98)00152-7 ↗
48. 10.1016/j.ijpharm.2006.05.02710.1016/j.ijpharm.2006.05.027 ↗
49. 10.1016/S0168-3659(02)00057-310.1016/S0168-3659(02)00057-3 ↗
50. 10.1016/j.sder.2004.06.00510.1016/j.sder.2004.06.005 ↗